SCHEMBL3875628

SCHEMBL3875628

CC(c1ccc(OCC(=O)Nc2ccc(-c3ccc(Cl)cc3)cc2)cc1F)N1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.56
CHRM1 P11229 1/20 0.56
HTR2A P28223 1/20 0.56
KMT2A Q03164 4/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GAA P10253 2/20 0.47
USP2 O75604 3/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALOX15 P16050 1/20 0.46
NR4A1 P22736 1/20 0.46
MAPK1 P28482 1/20 0.46
MCL1 Q07820 1/20 0.46
HTR2B P41595 1/20 0.45
KCNH2 Q12809 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3872374 0.90 MCHR1 (0.57) MCHR1CHRM1HTR2AKMT2AALDH1A1
SCHEMBL3869865 0.84 MCHR1 (0.66) MCHR1CHRM1HTR2AKMT2AALDH1A1
SCHEMBL3875635 0.79 MCHR1 (0.69) MCHR1CHRM1HTR2AKMT2AALDH1A1
SCHEMBL3868226 0.73 CHRM1 (0.74) MCHR1CHRM1HTR2AKMT2AALDH1A1
SCHEMBL3869748 0.73 CHRM1 (0.98) MCHR1CHRM1HTR2AKMT2AALDH1A1
SCHEMBL4014334 0.72 CHRM1 (1.00) MCHR1CHRM1HTR2AKMT2AALDH1A1
SCHEMBL3867601 0.72 MCHR1 (0.68) MCHR1CHRM1HTR2AKMT2AALDH1A1
SCHEMBL16082990 0.70 MEN1 (0.85) MCHR1CHRM1HTR2AKMT2AALDH1A1
SCHEMBL2610071 0.70 MEN1 (0.85) MCHR1CHRM1HTR2AKMT2AALDH1A1
SCHEMBL3869862 0.70 MCHR1 (0.71) MCHR1CHRM1HTR2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R MCHR1 4/4885CHRM1 217/4885HTR2A 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.